ArticleThe World Allergy Organization journal2026
Retrospective analysis of the efficacy and safety of 100 mg abrocitinib in patients with moderate to severe atopic dermatitis: Real-world study.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the real-world efficacy and safety of abrocitinib in Chinese patients with moderate to severe atopic dermatitis, while exploring the influence of prior dupilumab treatment on therapeutic outcomes. A single-center retrospective cohort study was conducted at the Department of Dermatology, Shenzhen Second People's Hospital, from July 2022 to December 2024. Materials: A total of 264 patients diagnosed with moderate to severe atopic dermatitis based on the Hanifin-Rajka criteria were enrolled. Participants were categorized into 2 groups: the initial abrocitinib group (n = 168) and the dupilumab-to-abrocitinib switch group (n = 96), depending on their previous exposure to dupilumab therapy. Treatment: The initial dose of abrocitinib was administered at 100 mg once daily for the first 12 weeks, followed by a gradual tapering schedule: 100 mg every other day from week 12 to week 36, and 100 mg every third day from week 36 to week 48. For 29 patients showing suboptimal response, the dosage was escalated to 200 mg once daily. Methods: The primary endpoints included the response rates for EASI-75/90, IGA 0/1 (defined as a reduction of ≥2 points from baseline), and PP-NRS4 at 48 weeks. Safety assessments involved monitoring adverse events (AEs). Statistical analyses were performed using SPSS software, including t-tests, analysis of variance, and chi-square tests. Results: At 48 weeks, the overall response rate for EASI-90 was 42.75%, and the PP-NRS4 response rate was 69.08%. The initial treatment group demonstrated significantly better outcomes compared to the switch group (EASI-90: 47.6% vs. 33.3%, p < 0.05). Regarding safety, 39.02% of patients experienced adverse events, primarily nausea (14.0%) and acne-like rash (11.0%), with no reports of serious adverse events or treatment discontinuation. Conclusion: Abrocitinib demonstrates rapid and sustained efficacy, particularly in alleviating pruritus, among Chinese patients with moderate to severe atopic dermatitis. The stepwise dose reduction regimen is both safe and feasible. Patients without prior dupilumab exposure exhibited superior therapeutic responses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.